Going to the dentist may not be fun but for those with periodontal disease related to type-two diabetes, a new research may bring back their smile.
Scientists have found that B cells – one of the most important blood cells involved in the human immune response – are shown to promote inflammation and bone loss in type-two diabetes-associated periodontal disease.
The treatments that manipulate the responses of B cells may treat or prevent the symptoms of type-two diabetes and periodontitis or pyorrhea simultaneously.
“Our study paves the way for the development of novel therapeutics which aim to simultaneously treat both type-two diabetes and its complications,” said Min Zhu, a researcher from department of microbiology at Boston University’s school of medicine.
To make this discovery, scientists used a mouse model of periodontal disease and applied it to two groups.
The first group had a genetic alteration that knocked out all B cells.
The second group had normal B cell levels.
When fed a low-fat diet, without development of obesity and type-two diabetes, both groups demonstrated a similar extent of oral bone loss and inflammation.
However, when they were fed a high-fat diet, oral bone loss and inflammation occurred in the normal group with B cells but did not develop in the group that had a genetic alteration that knocked out all B cells.
This suggests that the B cell-response might be a viable target for pharmacological intervention in both type-two diabetes and periodontal disease, as well as potentially in other type-two diabetes complications.
The research was published in the Journal of Leukocyte Biology.